Clik here to view.
Shionogi Further Extends Infectious Disease Innovation Platform with Planned...
OSAKA, Japan Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi Inc., a New Jersey-based subsidiary of...
View ArticleClik here to view.
Vertex Ventures HC Announces $200 Million Fund III to Drive Innovation in...
SAN FRANCISCO & BOSTON Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, is excited to announce the launch of its third and largest fund of $200 million. Fund III will be...
View ArticleClik here to view.
Vertex Ventures HC宣布设立2亿美元的第三支基金，以推动医疗保健创新
旧金山和波士顿 (美国商业资讯)– 由女性领导的全球医疗保健投资公司Vertex Ventures HC（VVHC）欣然宣布推出第三支也是最大的一支基金，规模达2亿美元。第三支基金将用于支持并增强开创性生命科学和医疗技术公司的能力，旨在推动创新和改善患者的治疗结果。 旧金山市场总监Lori Hu表示：...
View ArticleClik here to view.
バーテックス・ベンチャーズHCがヘルスケア産業改革へ向け2億ドルの3号ファンドを発表
サンフランシスコ＆ボストン （ビジネスワイヤ） — 女性主導の国際的ヘルスケア投資企業、バーテックス・ベンチャーズHC（VVHC）は、3度目のファンドかつ最大の額となる2億ドルのファンドの立ち上げを発表しました。3号ファンドは、イノベーションの推進と患者アウトカムの改善を目指し、ライフサイエンスおよび医療技術分野における先駆的企業の支援・後押しを目的として展開されます。...
View ArticleClik here to view.
Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program
NEW YORK Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at...
View ArticleClik here to view.
Sky Labs’ Paper on Cuffless Blood Pressure Measurement Technology Published...
SEOUL, South Korea Sky Labs, a healthcare company aiming to transform the healthcare industry with 24/7 monitoring in daily lives, announced that its report “Continuous cuffless blood pressure...
View ArticleClik here to view.
PanTheryx® Renews Exclusive Three-Year Partnership with VitaDairy® in...
PHOENIX PanTheryx®, Inc., an integrative digestive and immune health company, and VitaDairy®, the leading Vietnamese dairy company, announced the renewal of a multi-year strategic partnership today....
View ArticleClik here to view.
New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May...
TAIPEI PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced the publication of new results from a Phase 2 clinical study with...
View ArticleClik here to view.
After the Great Success Achieved in the United States and Canada, DEKA...
SINGAPORE DEKA, a subsidiary of the El.En. Group, a company listed on the Eurostar Next of the Italian Stock Exchange (ELN.MI), specialized in the development and manufacturing of cutting-edge...
View ArticleClik here to view.
アメリカ、カナダで大成功を収めたDEKA、シンガポールで開催された世界皮膚科学会で3つの特別なレーザーとマイクロ波のプラットフォームを発表
シンガポール （ビジネスワイヤ） — で開催された第25回世界皮膚科学会の機会に、先端の美容および外科用エネルギーベース機器の開発と製造を専門とする、イタリア証券取引所（ELN.MI）のEurostar Nextに上場しているEl.En. Groupのイタリア企業であるDEKAは、レーザーおよびマイクロ波機器をベースとした新しい「PRO」シリーズの発売を発表しました。...
View ArticleClik here to view.
CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM)...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
DiaCarta Announces the Termination of Business Combination Agreement with...
PLEASANTON, Calif. DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced the termination of its Business Combination Agreement with HH&L Acquisition Co. On June...
View ArticleClik here to view.
ASP Japan G.K. Informs the Opening of Yamato Factory – Toward Further Kaizen
TOKYO On July 1, 2023, ASP Japan, G.K. opened and began operations at its Yamato Factory in Yamato-city, Kanagawa Prefecture. This press release features multimedia. View the full release here:...
View ArticleClik here to view.
ASP Japan合同会社が大和工場を開設
東京 （ビジネスワイヤ） — 2023年7月1日、神奈川県大和市にASP Japan合同会社の大和工場を開設し、操業を開始いたしました。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20230703425148/ja/ ASP Japan合同会社 大和工場...
View ArticleClik here to view.
Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab...
ZUG, Switzerland Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology (WCD) in Singapore. The results highlight the rapid onset of...
View ArticleClik here to view.
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has...
View ArticleClik here to view.
First Distribution Agreement Executed with Sonic Healthcare
BRISBANE, Australia Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly...
View ArticleClik here to view.
与Sonic Healthcare签订首份分销协议
澳大利亚布里斯班 (美国商业资讯)– Microba Life Sciences Limited (ASX: MAP)（以下简称“Microba”）很高兴宣布，通过其全资子公司Douglass Hanly Moir Pathology Pty Ltd，与Sonic Healthcare Limited (ASX:...
View ArticleClik here to view.
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
BEIJING & LONDON Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an...
View ArticleClik here to view.
豪マイクロバ、ソニック・ヘルスケアと初の販売代理店契約を締結
豪ブリスベン （ビジネスワイヤ） — マイクロバ・ライフサイエンス（ASX：MAP、以下「マイクロバ」）は、ソニック・ヘルスケア（ASX：SHL）および完全子会社のダグラス・ハンリー・モア・パソロジー（Douglass Hanly Moir Pathology Pty Ltd）を介し、...
View Article